Mumbai: Swiss pharma major Novartis on Monday said it will not invest on research and development in India and move R&D to favourable destinations following the Supreme Court order rejecting its patent plea on cancer drug Glivec.

READ MORE: Novartis loses patent battle in SC

The company will continue to introduce products in the country, but not invest in R&D here, Novartis India Ltd Vice-Chairman and Managing Director Ranjit Shahani said at a press conference here. Novartis will move R&D investments to favourable destinations, he added. Shahani said the company will, however, keep filing patent applications for innovative products and continue to invest in India "but cautiously".
The Supreme Court on Monday rejected Swiss firm Novartis' patent plea for its cancer drug Glivec. A bench of justices Aftab Alam and Ranjana Prakash Desai dismissed the claim of the Swiss firm for getting exclusive rights for manufacturing the cancer drug on the ground that a new substance has been used in the medicine. While a one-month dose of Glivec costs around Rs 1.2 lakh generic drugs, manufactured by Indian companies, for the same period are priced at Rs 8,000. The Indian Patent Office had rejected the patent application of Novartis for the ß-polymorphic form of imatinib mesylate on various grounds in 2006, including that a patent could not be granted for the ß-polymorphic form under section 3(d) as it did not have any increase in efficacy over the previously known substance.

READ MORE: SC ruling breather for poor patients
Novartis appealed against the rejection of the patent by the Patent Office before the Intellectual Property Appellate Board (IPAB) in 2007, but the appeal was dismissed in 2009. Aggrieved by this dismissal, Novartis went to the Supreme Court which has now confirmed the rejection of the patent.

Novartis India says will continue to file for patents

Novartis India Ltd, a unit of Swiss drugmaker Novartis AG, will continue to file for patents in India, its vice chairman said on Monday, after the country's top court rejected its plea for patent protection of its drug Glivec.

Novartis India will also continue to invest there, but with caution, Ranjit Shahani, who is also the managing director of the company, told reporters after the judgment.


Latest News  from Business News Desk